Introduction

If you have been told your joint cartilage is worn or damaged, you may be weighing up the options available. For many years the standard surgical responses — debridement and microfracture — have been the main tools. A newer option, the ChondroFiller injection, now offers a non-surgical route that some patients consider as an alternative or intermediate step. This article sets out how these approaches differ, what each involves, and how to think about which might suit your situation.

Traditional Surgical Treatments

Debridement is a surgical technique in which loose or damaged tissue is removed from within the joint, typically under arthroscopic (keyhole) guidance. The aim is to reduce mechanical irritation and improve the joint environment. Microfracture is a bone-marrow stimulation technique: small perforations are made in the subchondral bone to encourage a healing response at the defect site. Both procedures are established in orthopaedic practice and can be appropriate in selected cases.

These are genuine surgical procedures. They require a theatre setting, anaesthesia, and a structured post-operative recovery. Results are variable and can depend on defect size, patient age, activity level, and the extent of wear (Steadman et al., 2001; Kreuz et al., 2006). Microfracture, in particular, tends to produce fibrocartilage rather than the hyaline-like cartilage that lines a healthy joint, which can limit its long-term durability in some patients (Frank et al., 2017).

ChondroFiller: A Non-Surgical Option

ChondroFiller is a Class III CE-marked medical device — a type I collagen hydrogel scaffold made by Meidrix Biomedicals, Germany, and available in the UK under prescription. It is acellular (cell-free) and self-gels within a few minutes of being applied. The CE Class III classification reflects the level of regulatory scrutiny applied to this device, including review of its clinical evidence.

As a non-surgical treatment, ChondroFiller is delivered as an ultrasound-guided outpatient injection directly into the joint. There is no incision, no theatre, and no general anaesthetic. Once inside the joint space, the collagen gel may settle over worn surfaces, forming a protective, cushioning layer. Its gel can absorb mechanical load and adapt to the forces within a joint (Weizel et al., 2020). Being acellular, the device works by recruiting the patient's own progenitor cells into the scaffold, which may support a biologically active repair environment.

ChondroFiller is best understood as a supportive, joint-preserving injection. In published clinical series, IKDC scores in the knee have improved by approximately 30 points over 12 to 36 months of follow-up, and modified Harris Hip Scores in the hip have improved by more than 30 points. MRI-based MOCART scores assessing repair tissue quality have reached around 80 and above in knee and hip studies. These figures reflect the device's published evidence, not a guaranteed outcome for any individual. ChondroFiller does not cure or reverse arthritis; benefits vary.

The injection has been used across a range of joints, including the knee, hip, ankle, and smaller joints such as the thumb base (trapeziometacarpal joint). The case for its use in the trapeziometacarpal joint has been supported by published case series (Corain et al., 2023).

ChondroFiller and Hyaluronic Acid Injections

Hyaluronic acid injections are widely used to ease joint symptoms, primarily through joint lubrication. ChondroFiller is different in composition and mechanism: it is a collagen-based scaffold rather than a lubricant, and its intended role is to add a protective, cushioning layer at the cartilage surface rather than to reduce friction alone. The two approaches are not directly equivalent and may suit different clinical situations. A specialist can help clarify which, if either, is appropriate for a particular joint and degree of wear.

Comparing the Options

The key practical difference is that debridement and microfracture are surgical procedures requiring theatre, anaesthesia, and recovery time, whereas ChondroFiller is a non-surgical outpatient injection with a more limited disruption to normal activity. However, non-surgical does not automatically mean more appropriate: defect size, joint access, the underlying degree of wear, and patient goals all influence which option makes clinical sense.

It is also worth noting that the Liquid Cartilage procedure — Professor Paul Y. F. Lee's keyhole surgical protocol at the London Cartilage Clinic — offers a distinct third pathway. Unlike the ChondroFiller injection, Liquid Cartilage is surgery: an arthroscopic procedure in which ChondroFiller is placed directly at the defect site during keyhole surgery, combined with biological adjuncts and, where indicated, the patient's own mesenchymal stem cells (MSC, sourced from bone-marrow concentrate or micro-fragmented fat). This protocol is suited to larger or more complex defects in load-bearing joints such as the knee, hip, shoulder, or ankle, where surgical placement offers advantages over injection alone. ChondroFiller injection and Liquid Cartilage are therefore related but distinct: they share the same scaffold material but differ fundamentally in delivery and surgical context.

Conclusion

Traditional surgical techniques such as debridement and microfracture remain established options for appropriate patients. The ChondroFiller injection provides a non-surgical alternative that may support joint preservation with less disruption for some people, particularly where lesions are accessible and surgical risk or recovery is a significant concern. For patients with larger or more complex defects, the Liquid Cartilage surgical protocol may be more suitable. The right choice is individual and depends on careful assessment.

At the London Cartilage Clinic (Harley Street), the clinical team offers specialist assessment of cartilage and joint-preservation options, including advice on whether the ChondroFiller injection, the Liquid Cartilage procedure, or another approach is most appropriate for your situation. A consultation can help clarify your options with realistic expectations.

References

• Weizel, A., Distler, T., Schneidereit, D., & Friedrich, O. (2020). Complex mechanical behavior of human articular cartilage and hydrogels for cartilage repair. Acta Biomaterialia.
• Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
• Steadman, J. R., Rodkey, W. G., & Rodrigo, J. J. (2001). Microfracture: surgical technique and rehabilitation to treat chondral defects. Clinical Orthopaedics and Related Research, 391 Suppl.
• Kreuz, P. C., Erggelet, C., Steinwachs, M. R., Krause, S. J., Konrad, G., & Niemeyer, P. (2006). Is microfracture of chondral defects in the knee associated with different results in patients aged 40 years or younger? Arthroscopy, 22(11), 1180–1186.
• Frank, R. M., Cotter, E. J., Nassar, I., & Cole, B. (2017). Failure of bone marrow stimulation techniques. Sports Medicine and Arthroscopy Review, 25(1), 2–9.